The importance of the US to the global pharmaceutical industry cannot be overstated. Home to many of the sector’s best performing companies, the country’s relatively lighter drug pricing controls and government support for R&D make it an extremely lucrative market to operate in.

After an enthralling US Election, Democratic nominee and former Vice-President Joe Biden is now US President Elect. While there is no doubt that his overall vision will differ immensely from that of outgoing President Donald Trump, it is less clear whether the new administration will mean big changes for healthcare and pharmaceuticals.

In this interview with Peter Loge, former senior advisor to the Food & Drug Administration Commissioner in the Obama Administration, we seek to shed some light on the potential impact of Biden’s election on issues that directly affect the industry, including drug pricing, manufacturing and R&D.

About the Speaker:

Peter Loge, Associate Professor of Media and Public Affairs, School of Media and Public Affairs, George Washington University

Peter has over 20 years of experience in communications including a presidential appointment at the Food and Drug Administration and senior positions for Sen. Edward Kennedy and three members of the US House of Representatives. He currently leads the Project on Ethics in Political Communication at the School of Media and Public Affairs.

Prior to joining the full-time faculty at SMPA, Peter served as a senior advisor to the commissioner of the Food and Drug Administration in the Obama administration, a presidential appointment. In this role, he developed and helped lead the strategic communication efforts for some of the top White House and FDA health priorities including the Cancer Moonshot, the Precision Medicine Initiative and combating the opioid crisis.